Dolphin Medical Services Ltd
₹ 6.51
5.00%
11 May
- close price
About
Incorporated in 1984, Dolphin Medical Services Ltd is in the business of diagnostics and
other allied services.[1]
Key Points
- Market Cap ₹ 9.83 Cr.
- Current Price ₹ 6.51
- High / Low ₹ 6.51 / 1.98
- Stock P/E 246
- Book Value ₹ 6.68
- Dividend Yield 0.00 %
- ROCE 0.64 %
- ROE 0.40 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.98 times its book value
Cons
- The company has delivered a poor sales growth of 9.80% over past five years.
- Promoter holding is low: 26.4%
- Company has a low return on equity of -0.30% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.36 | 0.57 | 0.35 | 0.15 | 0.06 | 0.18 | 0.47 | 0.52 | 0.61 | 0.68 | 0.78 | 0.75 | |
| 0.39 | 0.39 | 0.33 | 0.23 | 0.20 | 0.52 | 6.24 | 0.66 | 0.69 | 0.76 | 0.78 | 0.63 | |
| Operating Profit | -0.03 | 0.18 | 0.02 | -0.08 | -0.14 | -0.34 | -5.77 | -0.14 | -0.08 | -0.08 | 0.00 | 0.12 |
| OPM % | -8.33% | 31.58% | 5.71% | -53.33% | -233.33% | -188.89% | -1,227.66% | -26.92% | -13.11% | -11.76% | 0.00% | 16.00% |
| 0.01 | 0.15 | 0.02 | 0.09 | -0.63 | 0.05 | 5.55 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Interest | 0.05 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.52 | 0.34 | 0.33 | 0.33 | 0.24 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.09 |
| Profit before tax | -0.59 | -0.07 | -0.30 | -0.33 | -1.02 | -0.36 | -0.29 | -0.17 | -0.11 | -0.10 | -0.03 | 0.06 |
| Tax % | -3.39% | -28.57% | -10.00% | -12.12% | -1.96% | 5.56% | 6.90% | 5.88% | 9.09% | 10.00% | 0.00% | 33.33% |
| -0.57 | -0.05 | -0.27 | -0.30 | -1.01 | -0.39 | -0.31 | -0.19 | -0.12 | -0.10 | -0.03 | 0.04 | |
| EPS in Rs | -0.38 | -0.03 | -0.18 | -0.20 | -0.67 | -0.26 | -0.21 | -0.13 | -0.08 | -0.07 | -0.02 | 0.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 16% |
| 3 Years: | 33% |
| TTM: | 233% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 13% |
| 3 Years: | 57% |
| 1 Year: | 174% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 |
| Reserves | -2.30 | -2.34 | -2.61 | -2.91 | -3.91 | -4.30 | -4.61 | -4.80 | -4.92 | -5.03 | -5.06 | -5.02 |
| 8.05 | 8.16 | 8.21 | 8.21 | 6.22 | 6.37 | 0.61 | 0.68 | 0.76 | 0.80 | 0.87 | 0.87 | |
| 0.74 | 0.67 | 0.65 | 0.61 | 0.58 | 0.71 | 1.23 | 1.26 | 1.23 | 1.27 | 1.17 | 1.48 | |
| Total Liabilities | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.43 |
| 14.50 | 10.36 | 10.03 | 9.70 | 6.79 | 6.74 | 3.00 | 2.94 | 2.87 | 2.83 | 2.76 | 6.91 | |
| CWIP | 2.14 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 0.31 |
| Investments | 0.52 | 0.52 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| 4.43 | 4.78 | 4.98 | 4.97 | 4.86 | 4.80 | 4.83 | 4.80 | 4.80 | 4.81 | 4.82 | 4.80 | |
| Total Assets | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.43 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | -0.12 | -0.07 | 0.00 | 0.02 | -0.13 | 0.27 | -0.10 | -0.07 | -0.05 | -0.06 | 0.14 | |
| 0.00 | 0.01 | 0.03 | 0.00 | 1.97 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.45 | |
| -0.05 | 0.11 | 0.05 | 0.00 | -1.99 | 0.15 | -0.25 | 0.07 | 0.07 | 0.05 | 0.06 | 0.31 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 0.05 | -0.11 | -0.07 | 0.00 | 1.99 | -0.14 | 0.27 | -0.10 | -0.07 | -0.05 | -0.06 | -0.31 |
| CFO/OP | -167% | -56% | -200% | 0% | -14% | 38% | -5% | 71% | 88% | 62% | 117% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 | 36.50 |
| Days Payable | 73.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Cash Conversion Cycle | -36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 | 36.50 |
| Working Capital Days | 1,449.86 | 1,171.84 | 2,106.57 | 4,891.00 | 11,619.17 | 3,629.72 | 986.28 | 898.46 | 771.89 | 687.06 | 645.77 | 515.87 |
| ROCE % | -2.55% | -0.05% | -0.96% | -1.56% | -1.69% | -2.02% | -1.98% | -1.45% | -0.91% | -0.83% | -0.18% | 0.64% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Medical Materials Consumed INR |
|
|||||||||||
| Employee Benefit Expense INR |
||||||||||||
| Gross Block of Medical & Diagnostic Equipment INR |
||||||||||||
| Revenue from Diagnostic & Allied Services INR |
||||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Results: Audited Standalone Financial Results For The Quarter & Year Ended March 31, 2026.
16h - Dolphin Medical Services reported audited FY26 results, with board approval on 16 May 2026 and unmodified audit opinion.
-
Board Meeting Outcome for Audited Standalone Financial Results For The Quarter & Year Ended March 31, 2026.
16h - Dolphin Medical Services approved and filed audited FY26 and Q4 results on 16 May 2026.
-
Corporate Action-Intimation of Open Offer
1d - Acquirers to buy 26% of Dolphin Medical Services at ₹4.80, triggering control change.
-
Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer
1d - Public offer for 39,25,988 shares (26%) at ₹4.80; acquirers to gain control.
-
Board Meeting Intimation for Audited Financial Results For Quarter And Year Ended March 31, 2026
11 May - Board meeting on 16 May 2026 to approve audited Q4 and FY2026 financial results.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) DMSL provides a range of tests covering Radiology and Imaging, Biochemistry, Pathology, and Microbiology, etc., to the people of the coastal region of Andhra Pradesh.
b) Additionally, it has the eye care
division called the Dolphin Nethralaya
which is a comprehensive eye care
and a laser and research centre.
c) The company has also ventured
into IT and Biotechnology and Herbal
sectors